Eton Pharmaceuticals (NASDAQ:ETON – Get Rating) will be releasing its earnings data after the market closes on Thursday, March 16th. Analysts expect Eton Pharmaceuticals to post earnings of $0.01 per share for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.
Eton Pharmaceuticals Stock Down 2.3 %
ETON stock opened at $3.90 on Thursday. The company has a quick ratio of 3.42, a current ratio of 3.52 and a debt-to-equity ratio of 0.51. The firm has a market capitalization of $98.66 million, a PE ratio of -11.14 and a beta of 1.45. Eton Pharmaceuticals has a twelve month low of $1.95 and a twelve month high of $4.50. The stock has a 50-day simple moving average of $3.48 and a two-hundred day simple moving average of $2.87.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the business. Jane Street Group LLC purchased a new position in shares of Eton Pharmaceuticals during the fourth quarter worth about $43,000. Virtu Financial LLC bought a new stake in Eton Pharmaceuticals in the 2nd quarter worth approximately $67,000. Goldman Sachs Group Inc. bought a new stake in Eton Pharmaceuticals in the first quarter valued at approximately $77,000. PDT Partners LLC bought a new stake in Eton Pharmaceuticals in the first quarter valued at approximately $102,000. Finally, JPMorgan Chase & Co. bought a new stake in Eton Pharmaceuticals in the first quarter valued at approximately $106,000. Hedge funds and other institutional investors own 25.09% of the company’s stock.
Eton Pharmaceuticals Company Profile
Eton Pharmaceuticals, Inc engages in the development, acquisition, and commercialization of prescription drug products. Its products include Biorphen, Alaway Preservative Free, zonisamide oral suspension, topiramate oral suspension, lamotrigine for oral suspension, cysteine injection, and ephedrine ready-to-use injection.
- Get a free copy of the StockNews.com research report on Eton Pharmaceuticals (ETON)
- META Platforms May See its Biggest Opening Yet for New Highs
- Penny Stock Vinco Ventures Could Be Big Winner
- Is Chip Design Specialist Synopsys A Gem Hiding In Plain Sight?
- Should You Park Some Capital with Casey’s General Stores?
- Crowdstrike Stock: While The Iron Is Hot!
Receive News & Ratings for Eton Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.